The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

AIE materials for nucleus imaging

Emergence of a captivating phenomenon aggregation induced emission (AIE) in the early years of 21st century attracted worldwide researchers. In the last two decades various novel AIE active biocompatible small molecules, macromolecules and polymers have been developed for diverse biomedical applications. Imaging of specific organelle such as mitochondria, ribosomes, nuclei and many others play important in the controlling and successful treatment of various diseases. Conventional luminescent probe molecules used in the imaging at cellular or subcellular level exhibit very weak emission on dispersion or on aggregation in aqueous media. AIE luminogens development is indispensable to overcome the notorious aggregation-caused quenching (ACQ) issue inherited by conventional fluorophores. In the present chapter we mostly highlighted over one decade development of various AIE active luminogens utilized for imaging of cell nucleus, nucleon and nucleic acids. The development of those AIE luminogens exhibits promising results in the early diagnosis of cancer diseases.

Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[¹⁸F]fluorothymidine ([¹⁸F]FLT) positron emission tomography [¹⁸F]FLT-PET. [¹⁸F]FLT, unlike the most commonly used PET tracer [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [¹⁸F]FLT to diagnose, stage and assess response to therapy in lung cancer.

The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy

Targeting specific cell membrane markers for both diagnostic imaging and radionuclide therapy is a rapidly evolving field in cancer research. Some of these applications have now found a role in routine clinical practice and have been shown to have a significant impact on patient management. Several molecular targets are being investigated in ongoing clinical trials and show promise for future implementation. Advancements in molecular biology have facilitated the identification of new cancer-specific targets for radiopharmaceutical development.

Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care

PURPOSE OF REVIEW

This review highlights the status and developments of PET imaging in oncology, with particular emphasis on lung cancer. We discuss the significance of PET for diagnosis, staging, decision-making, monitoring of treatment response, and drug development. The PET key advantage, the noninvasive assessment of functional and molecular tumor characteristics including tumor heterogeneity, as well as PET trends relevant to cancer care are exemplified.

RECENT FINDINGS

Advances of PET and radiotracer technology are encouraging for multiple fields of oncological research and clinical application, including in-depth assessment of PET images by texture analysis (radiomics). Whole body PET imaging and novel PET tracers allow assessing characteristics of most types of cancer. However, only few PET tracers in addition to F-fluorodeoxyglucose have sufficiently been validated, approved, and are reimbursed for a limited number of indications. Therefore, validation and standardization of PET parameters including tracer dosage, image acquisition, post processing, and reading are required to expand PET imaging as clinically applicable approach.

SUMMARY

Considering the potential of PET imaging for precision medicine and drug development in lung and other types of cancer, increasing efforts are warranted to standardize PET technology and to provide evidence for PET imaging as a guiding biomarker in nearly all areas of cancer treatment.

Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux

Performing PET imaging during ongoing radionuclide therapy can be a promising method to follow tumor response in vivo. However, the high therapeutic activity can interfere with the PET camera performance and degrade both image quality and quantitative capabilities. As a solution, low-energy photon emissions from the therapeutic radionuclide can be highly attenuated, still allowing sufficient detection of annihilation photons in coincidence. Methods: Hollow Rose metal cylinders with walls 2-4 mm thick were used to shield a ²²Na point source and a uniform phantom filled with ¹⁸F as they were imaged on a preclinical PET camera with increasing activities of ¹⁷⁷Lu. A mouse with a subcutaneous tumor was injected with ¹⁸F-FDG and imaged with an additional 120 MBq of ¹⁷⁷Lu and repeated with shields surrounding the animal. Results: The addition of ¹⁷⁷Lu to the volume imaged continuously degraded the image quality with increasing activity. The image quality was improved when shielding was introduced. The shields showed a high ability to produce stable and reproducible results for both spatial resolution and quantification of up to 120 MBq of ¹⁷⁷Lu activity (maximum activity tested). Conclusion: Without shielding, the activity quantification will be inaccurate for time points at which therapeutic activities are high. The suggested method shows that the shields reduce the noise induced by the ¹⁷⁷Lu and therefore enable longitudinal quantitative intratherapeutic imaging studies.